Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2026 Sep 28;17:1954344. doi: 10.3389/fimmu.2026.1954344

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2026 Baltasar-Corral, García-Barragán, Zarza-Sanz, Buisán-Catevilla, Montero-Llorente, Rodríguez-Sagrado, Masjuan-Vallejo and Álvarez-Velasco.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Line graph and timeline track MG-ADL scores from 2020 to 2026, showing a general increase peaking in early 2025 before declining. Below, a treatment timeline lists Prednisone, Pyridostigmine, Azathioprine, 3,4-diaminopyridine, Mycophenolate, Rituximab, Plasma exchange, and Efgartigimod, each administered at different time periods. — Timeline of treatments, with moderate to no response up to efgartigimod initiation.